Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

This meta-analysis suggests that GLP-1 RAs therapy causes a significant reduction in CRP.